Zimislecel, a novel stem cell therapy, has reportedly demonstrated promising results in an early-phase clinical trial ...

In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) ...

During a clinical trial, around 83% (10 out of 12) of patients who received a full dose of Zimislecel achieved complete ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex ...

A new stem cell-based treatment helped most trial participants with severe type 1 diabetes stop insulin use, offering hope ...

Discover how zimislecel enables insulin independence in patients with Type 1 diabetes, showing strong efficacy in early ...

While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target ...

An early clinical trial of zimislecel, an allogeneic stem cell–derived islet therapy, restored insulin production and eliminated severe hypoglycemia in adults with type 1 diabetes.

In phase 2 of the FORWARD study, 83% of participants with type 1 diabetes achieved insulin independence a year after ...

US drugmaker Vertex Pharmaceuticals has announced simultaneous presentation and publication of updated data from the Phase ...

A cure for diabetes has been top of mind for many that live with the conditions under the term’s umbrella. But type 1 ...

Vertex Pharmaceuticals' stem cell therapy, Zimislecel, has shown potential to cure Type-1 diabetes, achieving insulin independence in 83% of patients during clinical trials.